Longer tamoxifen treatment cuts breast cancer deaths

The Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial, partly funded by AstraZeneca, found in the second decade after diagnosis women who continued on tamoxifen had a 25% lower recurrence rate and a 29% lower mortality rate than women who stopped treatment after five years.